EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation

Florian Klingler iD, Patrick Schlossbauer iD, Lukas Naumann, René Handrick, Friedemann Hesse, Christian Neusüß, Kerstin Otte

Biotechnology and Bioengineering · 2024

DOI: 10.1002/bit.28616 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2024. Written by Florian Klingler and 6 co-authors. Institution: Institute for Applied Biotechnology, University of Applied Sciences Biberach, Biberach, Germany. Major MEDLINE topics: MicroRNAs. Cited 5 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Bundesministerium für Bildung und Forschung.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

N‐linked glycosylation is one of the most important post‐translational modifications of monoclonal antibodies (mAbs) and is considered to be a critical quality attribute (CQA), as the glycan composition often has immunomodulatory effects. Since terminal galactose residues of mAbs can affect antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent cytolysis (CDC) activation, serum half‐life, and antiviral activity it has to be monitored, controlled and modulated to ensure therapeutic effects. The ability of small noncoding microRNAs (miRNAs) to modulate glycosylation in Chinese hamster ovary (CHO) production cells was recently reported establishing miRNAs as engineering tools for modulation of protein glycosylation. In this study, we report the characterization and validation of miRNAs as engineering tools for increased (mmu‐miR‐452‐5p, mmu‐miR‐193b‐3p) or decreased (mmu‐miR‐7646‐5p, mmu‐miR‐7243‐3p, mmu‐miR‐1668, mmu‐let‐7c‐1‐3p, mmu‐miR‐7665‐3p, mmu‐miR‐6403) degree of galactosylation. Furthermore, the biological mode of action regulating gene expression of the galactosylation pathway was characterized as well as their influence on bioprocess‐related parameters. Most important, stable plasmid‐based overexpression of these miRNAs represents a versatile tool for engineering N‐linked galactosylation to achieve favorable phenotypes in cell lines for biopharmaceutical production.

Subjects

MeSH terms (MEDLINE)

MicroRNAsAnimalsCricetinaeAntibodies, MonoclonalCHO CellsCricetulusGlycosylation

Author keywords

CHOgalactosylationglycosylationmicroRNAmonoclonal antibodies

Substances

MicroRNAsAntibodies, Monoclonal

Authors and institutions

  • Institute for Applied Biotechnology, University of Applied Sciences Biberach, Biberach, Germany.
  • Department of Chemistry, Aalen University, Aalen, Germany.

ORCID profiles: Florian Klingler, Patrick Schlossbauer

Funding

  • Bundesministerium für Bildung und Forschung

Cite

APA

Klingler, F., Schlossbauer, P., Naumann, L., Handrick, R., Hesse, F., Neusüß, C., & Otte, K. (2024). Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28616

Vancouver

Klingler F, Schlossbauer P, Naumann L, Handrick R, Hesse F, Neusüß C, et al. Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28616

BibTeX
@article{Klingler2024,
  author = {Klingler, Florian and Schlossbauer, Patrick and Naumann, Lukas and Handrick, René and Hesse, Friedemann and Neusüß, Christian and Otte, Kerstin},
  title = {Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  doi = {10.1002/bit.28616}
}
Start for free →